MX9301753A - Generacion in vitro de celulas dentriticas humanas y utilizacion de las mismas. - Google Patents

Generacion in vitro de celulas dentriticas humanas y utilizacion de las mismas.

Info

Publication number
MX9301753A
MX9301753A MX9301753A MX9301753A MX9301753A MX 9301753 A MX9301753 A MX 9301753A MX 9301753 A MX9301753 A MX 9301753A MX 9301753 A MX9301753 A MX 9301753A MX 9301753 A MX9301753 A MX 9301753A
Authority
MX
Mexico
Prior art keywords
same
vitro generation
dentritic cells
human
cells
Prior art date
Application number
MX9301753A
Other languages
English (en)
Inventor
Jacques Banchereau
Christophe Caux
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX9301753A publication Critical patent/MX9301753A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Abstract

Se proporciona un método para generar céluls dentríticas humanas in vitro, tratando células CD34+ con un factor alfa de necrosis tumoral e interleucina-3 o con GM-CSF.
MX9301753A 1992-03-30 1993-03-29 Generacion in vitro de celulas dentriticas humanas y utilizacion de las mismas. MX9301753A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP92400879A EP0563485A1 (en) 1992-03-30 1992-03-30 In vitro generation of human dendritic cells and uses thereof

Publications (1)

Publication Number Publication Date
MX9301753A true MX9301753A (es) 1993-09-01

Family

ID=8211642

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9301753A MX9301753A (es) 1992-03-30 1993-03-29 Generacion in vitro de celulas dentriticas humanas y utilizacion de las mismas.

Country Status (14)

Country Link
EP (2) EP0563485A1 (es)
JP (1) JP3492361B2 (es)
KR (1) KR100223395B1 (es)
AT (1) ATE192189T1 (es)
AU (2) AU682466B2 (es)
CA (1) CA2133316C (es)
DE (1) DE69328481T2 (es)
DK (1) DK0633930T3 (es)
ES (1) ES2145047T3 (es)
GR (1) GR3033761T3 (es)
MX (1) MX9301753A (es)
NZ (1) NZ251585A (es)
PT (1) PT633930E (es)
WO (1) WO1993020186A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2133409C (en) * 1992-04-01 2011-05-24 Ralph M. Steinman Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
DE4337396A1 (de) * 1993-10-26 1995-04-27 Beiersdorf Ag Humane Zellinien mit Langerhans-Zell-Charakteristik
DE4412794A1 (de) * 1994-04-14 1995-12-14 Univ Ludwigs Albert Verfahren zur Herstellung von dendritischen Zellen, so erhaltene Zellen und Behälter zur Durchführung dieses Verfahrens
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US6300090B1 (en) 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
US5648248A (en) * 1994-12-30 1997-07-15 Boehringer Ingelheim International Gmbh Methods for producing differentiated cells from immature hematopoietic cells
US6010905A (en) * 1995-01-27 2000-01-04 The United States Of America As Represented By The Department Of Health & Human Services Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells
US5643786A (en) * 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
US6340981B1 (en) 1997-06-30 2002-01-22 Sun Microsystems, Inc. Method and apparatus for stroke substitution
US5871728A (en) 1995-03-31 1999-02-16 University Of Pittsburgh Method of regulating dendritic cell maturation
US6121044A (en) * 1995-07-12 2000-09-19 Dendreon Corporation Potent antigen presenting cell composition
US7361330B2 (en) 1995-10-04 2008-04-22 Immunex Corporation Methods of using flt3-ligand in the treatment of fibrosarcoma
US7150992B1 (en) 1995-10-04 2006-12-19 Innunex Corporation Methods of preparing dendritic cells with flt3-ligand and antigen
US6734014B1 (en) 1996-02-08 2004-05-11 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating T cells
WO1997029183A2 (en) * 1996-02-08 1997-08-14 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating t cells
US7659119B2 (en) 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
US5811297A (en) * 1996-03-07 1998-09-22 Amba Biosciences, Llc Immortalized hematopoietic cell lines, cell system thereof with stromal cells, in vitro, ex vivo and in vivo uses, & in vitro generation of dendritic cells and macrophages
WO1998014561A1 (en) * 1996-10-04 1998-04-09 Becton Dickinson And Company Identification of a cd34+ bone marrow precursor for dendritic cells in blood and lymphoid tissues
CA2270898A1 (en) 1996-11-06 1998-05-14 The Regents Of The University Of California Isolated tumor necrosis factor receptor releasing enzyme, compositions comprising the enzyme and methods of the use thereof
AU9374198A (en) * 1997-09-08 1999-03-29 Idec Pharmaceuticals Corporation Methods for producing human antibodies in scid mice using dendritic cells
US6274378B1 (en) 1997-10-27 2001-08-14 The Rockefeller University Methods and compositions for obtaining mature dendritic cells
US6602709B1 (en) 1998-02-20 2003-08-05 The Rockefeller University Methods for use of apoptotic cells to deliver antigen to dendritic cells for induction or tolerization of T cells
EP1016413A1 (en) * 1998-12-30 2000-07-05 Applied Research Systems ARS Holding N.V. Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells
JP2001061469A (ja) * 1999-08-24 2001-03-13 Japan Science & Technology Corp 免疫応答誘導樹状細胞の調製方法
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7419957B2 (en) 2001-08-22 2008-09-02 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptides of melanoma antigen and their use in diagnostic, prophylactic and therapeutic methods
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
KR100522526B1 (ko) * 2002-11-28 2005-10-19 주식회사 바이넥스 면역 치료용 수지상 세포의 제조방법
WO2004104185A1 (en) 2003-05-08 2004-12-02 Xcyte Therapies, Inc. Generation and isolation of antigen-specific t cells
ATE489455T1 (de) 2004-10-07 2010-12-15 Argos Therapeutics Inc Zusammensetzungen reifer dendritischer zellen und verfahren zu deren kultivierung
WO2007055902A1 (en) 2005-11-03 2007-05-18 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Immunogenic peptides and methods of use for treating and preventing cancer
EP2728017B1 (en) 2007-11-19 2016-08-24 Celera Corporation Lung cancer markers and uses thereof
US8604166B2 (en) 2008-09-02 2013-12-10 Inserm (Institut National De La Sante Et De La Recherche Medicale) Melanoma antigen peptide and uses thereof
EP2714730A1 (en) 2011-06-01 2014-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel antigen peptide and uses thereof
US9475841B2 (en) 2012-05-22 2016-10-25 Inserm (Institut National De La Sante Et De La Recherche Medicale) Melanoma antigen peptide and uses thereof
AU2012380679A1 (en) 2012-05-22 2014-10-30 Centre National De La Recherche Scientifique (Cnrs) Novel melanoma antigen peptide and uses thereof
US10137181B2 (en) 2014-04-01 2018-11-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Isolated donor MHC-derived peptide and uses thereof
WO2015150491A1 (en) 2014-04-01 2015-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) An isolated donor mhc-derived peptide and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002531A1 (en) * 1989-08-17 1991-03-07 Peter Maccallum Cancer Institute Method for the modulation of haemopoiesis in a mammal
US5128259A (en) * 1989-10-27 1992-07-07 Hahnemann University Factor-dependent hematopoietic cell line exhibiting epo-induced erythrocyte maturation
US5622853A (en) * 1990-05-01 1997-04-22 Becton Dickinson And Company T lymphocyte precursor

Also Published As

Publication number Publication date
DE69328481T2 (de) 2000-09-07
JP3492361B2 (ja) 2004-02-03
AU3928993A (en) 1993-11-08
ATE192189T1 (de) 2000-05-15
EP0563485A1 (en) 1993-10-06
KR100223395B1 (ko) 1999-10-15
NZ251585A (en) 1997-07-27
AU3155897A (en) 1997-11-20
KR950700989A (ko) 1995-02-20
JPH07505527A (ja) 1995-06-22
ES2145047T3 (es) 2000-07-01
EP0633930B1 (en) 2000-04-26
DE69328481D1 (de) 2000-05-31
GR3033761T3 (en) 2000-10-31
CA2133316C (en) 2005-05-24
CA2133316A1 (en) 1993-10-14
DK0633930T3 (da) 2000-09-18
AU682466B2 (en) 1997-10-09
PT633930E (pt) 2000-09-29
EP0633930A1 (en) 1995-01-18
WO1993020186A1 (en) 1993-10-14

Similar Documents

Publication Publication Date Title
MX9301753A (es) Generacion in vitro de celulas dentriticas humanas y utilizacion de las mismas.
NO20001583D0 (no) Stimulering av hematopoetiske celler in vitro
ES8100457A1 (es) Perfeccionamientos en los dispositivos de borde iluminado
DE69738731D1 (de) SIALYL-LEWISa UND SIALYL-LEWISx EPITOPE ANALOGE
TR200001705T2 (tr) ''İmidazonaftiridinler ve bunların sitokin biyosentezinin indüklenmesinde kullanılması''
BG99177A (en) New 7 -substituted-4-aza-5 - cholestanones as inhibitors of 5 - reductase
KR970702733A (ko) 활성물질의 방출 조절용 콜라겐 제제(collagen preparation the controlled release of active substances)
DK0552243T3 (da) Anvendelse af interleukin-4 til behandling af faste tumorer
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
ATE377022T1 (de) Isolierte decapeptide, die an hla moleküle binden,sowie deren verwendung
HK1048649A1 (en) Modified cytokines for use in cancer therapy
ATE432978T1 (de) T-zellaktivierung
DK0565519T3 (da) Illudinanaloge som antitumormidler
ES2095846T3 (es) Composicion estable y liofilizada de un ester/eter de polihematoporfirina.
DE60327710D1 (de) Modifizierte zytokine für krebs therapie
ES2183890T3 (es) Uso del factor de crecimiento de hepatocitos para in estimular la proliferacion y diferenciacion de celulas hematopoyeticas.
EP0248217A3 (en) Treatment of tumors with autologous lak cells, interleukin-2 and an ornithine decarboxylase inhibitor
ATE311886T1 (de) Verwendung einer zusammensetzung enthaltend 5- androsten-3beta,17alpha-diol
ES2080114T3 (es) Procedimiento para preparar un factor inhibidor de la metastasis.
AU123393S (en) X-ray beam gradient
AU119855S (en) X-ray beam gradient
IT1274015B (it) Uso del ceruletide (takus) nel trattamento della psoriasi
AU87331S (en) An article of soft furnishing
AU87330S (en) An article of soft furnishing
AU87332S (en) An article of soft furnishing

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees